Study of Sinibolimab Combined with Lenvatinib As Neoadjuvant Therapy for Locally Advanced Unresectable Differentiated Thyroid Carcinoma

Clinical trial NCT06848920 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06848920
Sponsor: Zhejiang University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Differentiated Thyroid Carcinoma (DTC)Neoadjuvant Therapy

Start date: 2025-03-01
Primary completion: 2027-06-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.